Baseline, month-30 follow-up, and change from baseline for averaged per patient carotid intima–media thickness (CIMT) for six segments for patients having at least one post-baseline CIMT study (n=640)
| Variable | Rimonabant (n=313) | Placebo (n=327) | p Value |
| Baseline, mean (SD) | 0.816 (0.167) | 0.828 (0.171) | 0.38 |
| Month-30 end point, mean (SD) | 0.827 (0.170) | 0.840 (0.186) | 0.33 |
| Arithmetic change from baseline to month-30 end point, mean (SD) | 0.010 (0.095) | 0.012 (0.091) | 0.67* |
| Progression/year, mean (SD) | 0.005 (0.042) | 0.007 (0.043) | 0.45* |
| Month-30 end point, LS mean (SE) | 0.825 (0.010) | 0.845 (0.010) | |
| Progression/year, LS mean (SE) | 0.004 (0.002) | 0.006 (0.002) | |
| Difference in progression versus Placebo, LS mean (SE) | −0.002 (0.003) | 0.53† |
↵* p Value is from an analysis of covariance model with treatment as a factor and baseline CIMT as a covariate.
↵† LS means and p value are from a linear mixed model (Laird–Ware model) which includes treatment as a factor, time as a covariate and an interaction between treatment and time, with randomly varying intercepts and slopes.